The U.S. Food and Drug Administration is set to issue a warning to customers that a new type of CO2 filling and masking machine could be used to blow up their bodies, according to a new report.
The device is being developed by the pharmaceutical company Biogen, which says the machine has “proven to be safe and effective in the treatment of COVID-19.”
The warning, published in the journal Drug and Alcohol Dependence, is based on the fact that the machine can produce CO2, and can be installed on an electric fan and can operate up to 20 times a minute.
It states that the device can “increase the volume of CO 2 that can be extracted by up to 5% and produce a very low-level CO2.”
The report notes that the CO2 machine can also be used for COVID treatments, including breathing masking and nasal irrigation.
But it says the product is not designed to treat COVID infections.
The company did not immediately respond to Ars’ request for comment.
A BioMedTech spokesperson told Ars that the company is in the process of building a device to extract CO2 from blood samples, which is being tested on animals.
“The company is working with the FDA to develop a CO2 extraction technology that can remove CO2-contaminated blood,” the BioMedTek spokesperson said.
The BioMed Tek device is a CO 2 machine.
“There is no medical use for this product,” the spokesperson said, referring to the product as a “non-medical product.”
A spokesperson for the Drug and Control Agency confirmed to Ars that Biogen is working on a COX-2 machine.
The DEA does not regulate COX medications.
But the agency has said that it’s concerned about the risks posed by the COX drugs.
In a statement sent to Ars, the DEA said that the agency is aware of the new COX2 machine and that it “has not yet determined the safety of this product.”
The agency also said that there’s “no evidence to show that the product’s safety is warranted” and said it would take action if the company continues to develop and market products that could pose a health risk.
In response to questions from Ars, Biogen did not respond to repeated requests for comment on the safety issues with its COX machine.